How Do You Switch Between SSRIs Safely?
Most SSRI-to-SSRI switches can be done directly — stop drug A, start drug B next day at a starting dose. Cross-taper over 2 weeks for high doses or mixed mechanisms. Fluoxetine requires a 5-week washout before starting an MAOI because of its long half-life and active metabolite. Never combine SSRI + MAOI — fatal serotonin syndrome risk.
Evidence review
Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.
STAR*D Level 2 switch (2006)
PMID 16554525727 patients non-remitting on citalopram
Direct switch to sertraline, venlafaxine, or bupropion — 21–27% remission. Time to remission similar across strategies.
Schatzberg et al. antidepressant discontinuation consensus (2006)
PMID 16683860Consensus panel review of SSRI/SNRI discontinuation literature
Short-half-life agents (paroxetine, venlafaxine) carry highest discontinuation-symptom risk; fluoxetine carries the lowest because of its long active metabolite. Recommend tapering over 2–4 weeks when feasible.
Practical decision algorithm
| If | Then |
|---|---|
| Switching between similar SSRIs at low-moderate dose (e.g., sertraline → escitalopram) | Direct switch — stop drug A, start drug B at therapeutic starting dose next day. |
| High-dose SSRI → different mechanism (SNRI, bupropion, mirtazapine) | Cross-taper over 2 weeks — reduce A by 50% weekly, add B at starting dose. |
| Switching from fluoxetine | Stop fluoxetine; wait 5 weeks if switching to MAOI; 7 days is adequate before other SSRIs given residual active metabolite. |
| Switching from paroxetine or venlafaxine | Taper over 2–4 weeks to avoid discontinuation syndrome; then start new agent. |
| Switch for treatment resistance | Confirm 6–8 weeks at therapeutic dose before switching. Consider augmentation (aripiprazole, bupropion, lithium) rather than switch. |
Guideline position
APA 2019 Clinical Practice Guideline for Treatment of Depression: switch to a different antidepressant is a reasonable option after inadequate response. NICE NG222 (2022) depression guideline: most SSRI-to-SSRI switches can be direct; cross-taper is recommended when switching across classes or from drugs with discontinuation risk.
Contraindications and cautions
- MAOI bridge period <14 days (5 weeks from fluoxetine) — serotonin syndrome
- Concurrent linezolid, methylene blue, tramadol — serotonin syndrome risk
- Active unstable bipolar disorder
- History of SSRI-induced mania